For the last 20 years, Marc has been applying mathematical M&S techniques to problems in clinical pharmacology and drug development across industrial, government, and academic settings. Marc provides the scientific and thought leadership for MetrumRG.
Janelle Hajjar, Jeannine Fisher, Marc R. Gastonguay. Trends in the application of pharmacometric modeling and simulation in the development of orphan drugs in the 21st century. ACoP6. October 2015.
Rena J. Eudy, William R. Gillespie, Matthew M. Riggs, Marc R. Gastonguay. Linking a Mechanistic Model of Bone Mineral Density to a Time-To-Event Model of Fracture. ACoP 6. October 2015.
Kyle T. Baron and Marc R. Gastonguay. Simulation from ODE-based population PK/PD and systems pharmacology models in R with mrgsolve. ACoP 6. October 2015.
Marc R. Gastonguay. A Pharmacometrician’s Perspective for Utilization of Big Data. ACoP 6. 2015.
Marc R. Gastonguay and CJ Godfrey. Modeling & Simulation: Filling the Knowledge Gap in Rare Diseases. Return on Investment on the Utilization of Systems Pharmacology and Pharmacometrics in Drug Development for Rare Diseases: Challenges and Opportunities, ACCP Workshop, September 26, 2015.
RJ Eudy, MR Gastonguay, KT Baron, and MM Riggs.Connecting the Dots: Linking Osteocyte Activity and Therapeutic Modulation of Sclerostin by Extending a Multiscale Systems Model. CPT Pharmacometrics Syst. Pharmacol. 2015 Sep; 4(9): 527-536.
Eudy RJ, Gastonguay MR, Baron KT, Riggs MM. Sclerostin-Mediated Osteocyte Control in Bone Remodeling: Extension of a Multiscale Systems Model to Consider New Therapies for Osteoporosis. PAGE 24 (2015) Abstr 3355
Alanna S. Ocampo-Pellend, Marc R. Gastonguay, Jonathan L. French, Matthew M. Riggs. Model-based Meta-analysis for Development of a Population-Pharmacokinetic (PPK) Model for Vitamin D3 and its 25OHD3 Metabolite. PAGE 2015.
P. A. Stricker, M. R. Gastonguay, D. Singh, J. E. Fiadjoe, E. M. Sussman, E. Y. Pruitt, T. K. Goebel, and A. F. Zuppa. Population pharmacokinetics of ε-aminocaproic acid in adolescents undergoing posterior spinal fusion surgery. British Journal of Anaesthesia, 2015.
Jin Y, Bies R, Gastonguay MR, Wang Y, Stockbridge N, Gobburu J, Madabushi R. Predicted impact of various clinical practice strategies on cardiovascular risk for the treatment of hypertension: a clinical trial simulation study. J Pharmacokinet Pharmacodyn. 2014 Dec;41(6):693-704.
Daniel G. Polhamus, Jia Kang, James A. Rogers, and Marc R. Gastonguay. Web-based Software for Real-time Simulation-assisted Trial Design in Alzheimer’s Disease. CTAD 2014.
Knebel W, Rogers J, Polhamus D, Ermer J, Gastonguay MR. Modeling and simulation of the exposure-response and dropout pattern of guanfacine
extended-release in pediatric patients with ADHD. J Pharmacokinet Pharmacodyn. 2014 Nov 6.
Rena J. Eudy and Marc. R. Gastonguay. Establishing A Priori Identifiability of Target Mediated Drug Disposition Models. ACoP5. October 2014.
Alanna S. Ocampo-Pelland, Marc R. Gastonguay, Joseph A. Lorenzo, and Matthew M. Riggs. Model-based Meta-analysis for Development of a Population-Pharmacokinetic (PPK) Model for Vitamin D. ASBMR 2014 Annual Meeting.
P. Ravva, M. R. Gastonguay, H. M. Faessel, T. C. Lee, and R. Niaura. Pharmacokinetic-pharmacodynamic modeling of the effect of varenicline on nicotine craving in adult smokers. Nicotine Tob Res, Aug 2014.
W. Knebel, J. Ermer, J. Purkayastha, P. Martin, and M. R. Gastonguay. Population pharmacokinetic/pharmacodynamic modeling of guanfacine effects on QTc and heart rate in pediatric patients. AAPS J, Aug 2014.
M. M. Riggs, L. J. Seman, A. Staab, T. R. MacGregor, W. Gillespie, M. R. Gastonguay, H. J. Woerle, and S. Macha. Exposure-response modelling for empagliflozin, a sodium glucose cotransporter 2 (sglt2) inhibitor, in patients with type 2 diabetes. Br J Clin Pharmacol, Jun 2014.
J. S. Gewandter, R. H. Dworkin, D. C. Turk, M. P. McDermott, R. Baron, M. R. Gastonguay, I. Gilron, N. P. Katz, C. Mehta, S. N. Raja, S. Senn, C. Taylor, P. Cowan, P. Desjardins, R. Dimitrova, R. Dionne, J. T. Farrar, D. J. Hewitt, S. Iyengar, G. W. Jay, E. Kalso, R. D. Kerns, R. Leff, M. Leong, K. L. Petersen, B. M. Ravina, C. Rauschkolb, A. S. C. Rice, M. C. Rowbotham, C. Sampaio, S. H. Sindrup, J. W. Stauffer, I. Steigerwald, J. Stewart, J. Tobias, R.-D. Treede, M. Wallace, and R. E. White. Research designs for proof-of-concept chronic pain clinical trials: Immpact recommendations. Pain, May 2014.
C. J. Endres, D. H. Salinger, K. Köck, M. R. Gastonguay, D. A. Martin, P. Klekotka, A. Nirula, and M. A. Gibbs. Population pharmacokinetics of brodalumab in healthy adults and adults with psoriasis from single and multiple dose studies. J Clin Pharmacol, May 2014.
Population pharmacokinetics of empagliflozin, a sodium glucose cotransporter 2 inhibitor, in patients with type 2 diabetes. Riggs MM, Staab A, Seman L, Macgregor TR, Bergsma TT, Gastonguay MR, Macha S. J Clin Pharmacol. 2013 Aug 13.
Timothy Bergsma, William Knebel, Daniel Polhamus, Jeffrey T. Hane, Marc R. Gastonguay. A Cloud-Based Cluster Computing Platform for Pharmacometric Applications. ACoP 2013.
Knebel W, Gastonguay MR, Malhotra B, El-Tahtawy A, Jen F, Gandelman K. Population Pharmacokinetics of Atorvastatin and Its Active Metabolites in Children and Adolescents With Heterozygous Familial Hypercholesterolemia: Selective Use of Informative Prior Distributions from Adults. J Clin Pharmacol. Feb 4, 2013 [Epub ahead of print].
Stricker PA, Zuppa AF, Fiadjoe JE, Maxwell LG, Sussman EM, Pruitt EY, Goebel. TK, Gastonguay MR, Taylor JA, Bartlett SP, Schreiner MS. Population pharmacokinetics of epsilon-aminocaproic acid in infants undergoing craniofacial reconstruction surgery. British Journal of Anaesthesia. First published online January 25, 2013.
Bergsma TT, Knebel W, Fisher J, Gillespie WR, Riggs MM, Gibiansky L, Gastonguay MR. Facilitating pharmacometric workflow with the metrumrg package for R. Comput Methods Programs Biomed. 2013 Jan;109(1):77-85.
William Knebel, Jim Rogers, Dan Polhamus, Sharon Youcha, Carla White, Jim Ermer, and Marc Gastonguay. Modeling and Simulation of Guanfacine Extended-Release to Support Pediatric Trial Design. American Academy of Child and Adolescent Psychiatry, 59th Annual Meeting. 2012.
Matthew M. Riggs, Kyle T. Baron, Elodie L. Plan, Marc R. Gastonguay. Qualification of a Physiologically-Based Model for Predicted Bone Marker and Bone Mineral Density Changes Associated with Denosumab Treatment. Presented at American Society of Bone Mineral Research (ASBMR) Annual Meeting, Minneapolis, MN; October 14, 2012 (Abstract# SU0363).
Rogers JA, Polhamus D, Gillespie WR, Ito K, Romero K, Qiu R, Stephenson D, Gastonguay MR, Corrigan B. Combining patient-level and summary-level data for Alzheimer’s disease modeling and simulation: a beta regression meta-analysis. J Pharmacokinet Pharmacodyn. October 2012, Volume 39, Issue 5, pp 479-498.
Knebel W, Rao N, Uchimura T, Mori A, Fisher J, Gastonguay MR, Chaikin P. Population pharmacokinetic-pharmacodynamic analysis of istradefylline in patients with Parkinson disease. J Clin Pharmacol. 2012 Oct;52(10):1468-81.
Bergsma TT, Knebel W, Fisher J, Gillespie WR, Riggs MM, Gibiansky L, Gastonguay MR. Facilitating pharmacometric workflow with the metrumrg package for R. Comput Methods Programs Biomed. 2012 Sep 28.
James Rogers, Peter Lockwood, Dan Polhamus, Yves Brault, Anne Desmet, Kaori Ito, Klaus Romero, Ruolun Qiu, Bill Gillespie, Brian Corrigan, Marc Gastonguay. Model-based Analysis to Support Strategic Decision Making: A Case Study from the Development of a 5HT6 Antagonist for the Treatment of Alzheimer’s Disease.
Dan Polhamus, Jim Rogers, Bill Gillespie, Jonathan French, and Marc Gastonguay. From Evidence Synthesis to Trial Optimization: The adsim Package for Model-based Simulation in Alzheimer’s Disease. PAGE 21 (2012).
Elodie L. Plan, Kyle T. Baron, Marc R. Gastonguay, Jonathan L. French, William R. Gillespie, and Matthew M. Riggs. Bayesian Joint Modeling of Bone Mineral Density and Repeated Time-To-Fracture Event for Multiscale Bone Systems Model Extension. PAGE 21 (2012) Abstr 2592.
Jin Y, Bies R, Gastonguay MR, Stockbridge N, Gobburu J, Madabushi R. Misclassification and discordance of measured blood pressure from patient’s true blood pressure in current clinical practice: a clinical trial simulation case study. J Pharmacokinet Pharmacodyn. 2012 Jun;39(3):283-94.
M. M. Riggs, T. T. Bergsma, J. A. Rogers, M. R. Gastonguay, G. M. Subramanian, C. Chen, M. Devalaraja, A. E. Corey, H. Sun, J. Yu, and D. S. Stein. Population pharmacokinetics and exposure-response of albinterferon alfa-2b. J Clin Pharmacol, 52(4):475–86, Apr 2012.
D’Argenio DZ, Gastonguay MR, Brundage RC, Miller R, Tannenbaum SJ, Pfister M. Affiliation between the American Society of Pharmacometrics and the Journal of Pharmacokinetics and Pharmacodynamics. J Pharmacokinet Pharmacodyn. 2012 Feb;39(1):3.
Riggs MM, Peterson MC, Gastonguay MR. Multiscale physiology-based modeling of mineral bone disorder in patients with impaired kidney function. J Clin Pharmacol. 2012 Jan;52(1 Suppl):45S-53S.
Gastonguay MR. Application of Modeling and Simulation to Support Clinical Drug Development Decisions in Alzheimer’s Disease. 2011.
Zuppa AF, Nicolson SC, Barrett JS, Gastonguay MR. Population pharmacokinetics of pentobarbital in neonates, infants, and children after open heart surgery. J Pediatr. 2011 Sep;159(3):414-419.e1-3.
Gastonguay MR. Full Covariate Models as an Alternative to Methods Relying on Statistical Significance for Inferences about Covariate Effects: A Review of Methodology and 42 Case Studies. PAGE 20 (2011) Abstr 2229.
Feng Y, Gastonguay MR, Pollock BG, Frank E, Kepple GH, Bies RR. Performance of Cpred/Cobs concentration ratios as a metric reflecting adherence to antidepressant drug therapy. Neuropsychiatr Dis Treat. 2011;7:117-25.
Gibbs JP, Emery MG, McCaffery I, Smith B, Gibbs MA, Akrami A, Rossi J, Paweletz K, Gastonguay MR, Bautista E, Wang M, Perfetti R, Daniels O. Population pharmacokinetic/pharmacodynamic model of subcutaneous adipose 11β-hydroxysteroid dehydrogenase type 1 (11β-HSD1) activity after oral administration of AMG 221, a selective 11β-HSD1 inhibitor. J Clin Pharmacol. 2011 Jun;51(6):830-41.
Kyle T. Baron, Patanjali Ravva, Vivek Purohit, Matthew M. Riggs, Marc R. Gastonguay. Evaluation of Rapid and Sustained Population Viral Response Rates Predicted Under Hepatitis C Viral Dynamic Models. 6th International Workshop on Clinical Pharmacology of Hepatitis Therapy, June 2011.
Polhamus, D, Baron KT, Purohit, VS, Ravva P, Rogers, JA, Gastonguay MR. A Time to Event Approach for Standard of Care Meta-Analysis in HCV Trials. Presented at ACOP 2011, San Diego, CA
Cirrincione-Dall G, Gastonguay MR, Knebel, W, Bergsma T, Zhang AY, Patel D, Barrett JS, van Schaik R, Soldin OP, Soldin SJ, Nulmin I, Koren G, de Wildt SN. A Population Pharmacokinetic Model of Tacrolimus in Pediatric Liver Transplant Recipients. Presented at ACOP 2011, San Diego, CA.
Bergsma T, Fisher J, Gastonguay MR, Hane J, Knebel W, Riggs MM, Rogers JA. Systematic Review of Versioned Files for Modeling and Simulation Quality Control: The“review” R Package. Presented at ACOP 2011, San Diego, CA.
Baron K, Ravva P, Purohit V, Riggs MM, Gastonguay MR. Evaluation of Rapid and Sustained Population Viral Response Rates Predicted Under Hepatitis C Viral Dynamic Models. Presented at ACOP 2011, San Diego, CA.
Knebel W, Tammara B, Udata C, Comer G, Gastonguay MR, Meng X. Population pharmacokinetic modeling of pantoprazole in pediatric patients from birth to 16 years. J Clin Pharmacol. 2011 Mar;51(3):333-45.
Rogers JA, Ito K, Gillespie WR, Corrigan BW, Gastonguay MR. A Longitudinal Dose-response Model for the Progression of Alzheimers Disease, Based on a Combination of Summary-level and Patient-level Data. Presented at Fourth Annual Bayesian Biostatistics Conference, Houston, TX, Jan 26–28, 2011.
Knebel W, Rao N, Uchimura T, Mori A, Fisher J, Gastonguay MR, Chaikin P. Population pharmacokinetic analysis of istradefylline in healthy subjects and in patients with Parkinson’s disease. J Clin Pharmacol. 2011 Jan;51(1):40-52.
Riggs MM, Gastonguay MR, Peterson MC. A physiologically-based, multiscale model used to predict progressive bone mineral density loss due to chronic renal disease. Presented at 2010 American Association of Pharmaceutical Scientists (AAPS) Annula Meeting, New Orleans LA; November 17, 2010; Poster # W4403
Riggs MM, Gillespie WR, Gastonguay MR, Peterson MC. Extension of a Multiscale Model of Calcium Homeostasis and Bone Remodeling to Include the Progressive Effects of Estrogen Loss During Menopause Transition. Presented at National Institute of General Medical Sciences Quantitative Systems Pharmacology Workshop II. Bethesda, MD; September 9, 2010.
Romero K, Corrigan B, Tornoe CW, Gobburu JV, Danhof M, Gillespie WR, Gastonguay MR, Meibohm B, Derendorf H. Pharmacometrics as a discipline is entering the “industrialization” phase: standards, automation, knowledge sharing, and training are critical for future success. J Clin Pharmacol. 2010 Sep;50(9 Suppl):9S-19S.
Pfister M, Brundage RC, Gastonguay MR, Miller R, Tannenbaum SJ, D’Argenio DZ. Defining the future of pharmacometrics: the American Society of Pharmacometrics. J Clin Pharmacol. 2010 Sep;50(9 Suppl):158S.
Brundage RC, Pfister M, D’Argenio DZ, Gastonguay MR, Miller R, Tannenbaum SJ. ACoP: the tools, carpenters, and architects building the discipline of pharmacometrics. J Clin Pharmacol. 2010 Sep;50(9 Suppl):7S-8S.
Knebel W, Bergsma TT, Dagdigian C, Hane J, Gastonguay MR. Utilizing NONMEM 7 and the Intel Fortran Compiler in a Distributed Computing Environment. PAGE 2010.
Gastonguay MR, Gillespie WR, Bauer RJ. Comparison of MCMC simulation results using NONMEM 7 or WinBUGS with BUGSModelLibrary. PAGE 2010.
Su F, Nicolson SC, Gastonguay MR, Barrett JS, Adamson PC, Kang DS, Godinez RI, Zuppa AF. Population pharmacokinetics of dexmedetomidine in infants after open heart surgery. Anesth Analg. 2010 May;110(5):1383-92.
Nathanael Dirks, Marc R. Gastonguay, William R. Gillespie, William Knebel, Matthew M. Riggs, John C. Panetta, and Bernd Meibohm. Comparative Performance of Bayesian Markov Chain Monte Carlo and Maximum Likelihood Population Estimation Methods when Applied to Nonlinear Pharmacokinetics of Monoclonal Antibodies. Presented at ASCPT 111th Annual Meeting, March 17-20, 2010
Sweeney KR, Gastonguay MR, Benincosa L, Cronenberger CL, Glue P, Malhotra BK . Exposure-response modeling and clinical trial simulation of the effect of tolterodine on QT intervals in healthy volunteers. Drug Discov Ther. 2010 ;4(1):44-53.
JP Ravva, M.R.Gastonguay, J.L. French, T G Tensfeldt, and H M Faessel. Quantitative Assessment of Exposure–Response Relationships for the Efficacy and Tolerability of Varenicline for Smoking Cessation. Clinical Pharmacology & Therapeutics (2010) 87 3, 336–344.
Marc R. Gastonguay. The Impact of Missing Data on Model Evaluation. ACOP 2009.
James A. Rogers, Matthew M. Riggs, Monte Cofﬁner, William R. Gillespie, Robert Burford, Francis Vanderbist, Sophie De Niet, Marc R. Gastonguay. Clinical Trial Simulation to Compare Adaptive and Fixed Designs for a Phase 3 Clinical Trial of Nacystelyn® (L-Lysine-N-acetyl-L-cysteinate) for Cystic Fibrosis. ACOP 2009.
William R. Gillespie, James A. Rogers, Kaori Ito, Marc R. Gastonguay. Population Dose-Response Model for ADAS-cog Scores in Patients with Alzheimers Disease by Meta-Analysis of a Mixture of Summary and Individual Data.
Timothy Bergsma, Jeffrey Hall, Michael S. Smith, Malaz A. AbuTarif, David R. Taft, William Knebel, Joseph Hebert, James Rogers, Jeffrey T. Hane, and Marc R. Gastonguay. Development and Pilot Evaluation of a High-Performance Computing System for Web-Based Deployment of Pharmacometrics Applications in a Multi-User Training Environment. ACOP 2009.
Nicholas T, Knebel W, Gastonguay MR, Bednar MM, Billing B, Landen JW, Kupiec JW, Corrigan B, Laurencot R, Zhao Q. Preliminary population pharmacokinetic modeling of PF-04360365, a humanized anti-amyloid monoclonal antibody, in patients with mild-to-moderate Alzheimer’s disease. ICAD 2009.
Gillespie B, Rogers JA, Ito K, Gastonguay MR. Population Dose-Response Model for ADAS-cog Scores in Patients with Alzheimer’s Disease by Meta-Analysis of a Mixture of Summary and Individual Data. ASCPT 110th Annual Meeting, March 18-21, 2009.
Riggs MM, Peterson MC, Gastonguay MR. A Systems Biology Model to Describe Long-Term Bone Remodeling Effects of Estrogen in Menopausal and Postmenopausal Women.
Gillespie B, Gastonguay MR. Prototype Model Library for Bayesian Pharmacokinetic/Pharmacodynamic (PKPD) Modeling in Winbugs.
Knebel W, Palmen M, Dowell JA, Gastonguay M. Population pharmacokinetic modeling of epoetin delta in pediatric patients with chronic kidney disease. J Clin Pharmacol. 2008 Jul;48(7):837-48.
Riggs MM, Bergsma TT, Gillespie WR, Gastonguay MR, Sprenger KJ. Use of Rpad, an Open-Source, Interactive, Web-Based Analysis Program, for Visualization During Model-Based Drug Development of Adipiplon, a GABAA Receptor Partial Agonist Under Investigation for the Treatment of Insomnia. American Conference on Pharmacometrics, 2008.
Knebel W, Bergsma T, Fisher J, Georgalis G, Gibiansky L, Gillespie WR, Riggs MM, and Gastonguay MR. Facilitating the Pharmacometrics Work-Flow with the MItools R Package. American Conference on Pharmacometrics, 2008.
Gillespie WR, Gastonguay MR, Knebel W, Georgalis G. Open Source Software Tools for Parallel Computation of Multiple MCMC Chains with WinBUGS. American Conference on Pharmacometrics, 2008.
Fisher J, Gastonguay MR, Knebel W, Gibiansky L, Wire MB. Population Pharmacokinetic Modeling of Fosamprenavir in Pediatric HIV-Infected Patients. American Conference on Pharmacometrics, 2008.
W.R. Gillespie, M.R. Gastonguay, W. Knebel. Bayesian Approaches to Mixed Effects Models for Ordered Categorical Data. AAPS Annual Meeting, San Diego, November 2007.
Knebel W, Rao N, Bergsma T, Gastonguay M, Mori A, Uchimura T, Allenby K, Dvorchik B, Sussman N, Chaikin P. Population Pharmacokinetic-Pharmacodynamic Modeling of Istradefylline in Patients With Parkinson’s Disease. ACCP 2007.
Faessel HM, Rawa P, Gastonguay MR, Rohrbacher KD, Tenfeldt TG. Population Pharmacokinetic Analysis of Varenicline in Adult Smokers. Clin Pharmacol Ther 2007; 81(S1), Abstract PI-26: S20-21.
Rawa P, Faessel H, Gastonguay MR, Tensfeldt TG, Reeves K. Quantitative Assessment of Exposure-Response Relationships for the Efficacy and Tolerability of Varenicline for Smoking Cessation. Clin Pharmacol Ther 2007; 81(S1), Abstract PII-73: S72.
Agoram B, Heatherington AC, Gastonguay MR. Development and evaluation of a population pharmacokinetic-pharmacodynamic model of darbepoetin alfa in patients with nonmyeloid malignancies undergoing multicycle chemotherapy. AAPS Journal. 8(3), 2006.
Gastonguay MR, Gibiansky L. Acknowledging and Incorporating Uncertainty in Model-Based Inferences. ECPAG Conference (2006) Workshop Poster Session, Abstract.
Mondick JT, Gibiansky L, Gastonguay MR, Veal GJ, Barrett JS. Acknowledging parameter uncertainty in the simulation-based design of an actinomycin-D pharmacokinetic study in pediatric patients with Wilms’ Tumor or rhabdomyosarcoma. PAGE 2006 (2006) Abstract 938.
Gibiansky L and MR Gastonguay. R/NONMEM Toolbox for Simulation from Posterior Parameter (Uncertainty) Distributions. L. Gibiansky and M.R. Gastonguay. PAGE 2006 (2006) Abstract 958.
Gastonguay MR, Gibiansky L. Acknowledging Parameter Uncertainty by Simulating from Posterior Distributions with NONMEM and R. MUFPADA Annual Meeting (2006) Abstract.
Knebel B, Bergsma T, Gibiansky L, Hane JT, Gastonguay MR. NMQual: A Tool to Automate Installation and Facilitate Qualification of NONMEM. PAGE Annual Meeting: Abstracts, 2005.
Gastonguay MR, El-Tahtawy A. Modeling and Simulation Guided Design of a Pediatric Population Pharmacokinetic Trial for Hydromorphone. The AAPS Journal. Vol. 7, No. S2, Abstract W5318, 2005.
Gastonguay MR and El-Tahtawy A. Effect of NONMEM Minimization Status and Number of Replicates on Bootstrap Parameter Distributions for Population Pharmacokinetic Models: A Case Study. Clinical Pharmacology and Therapeutics. 77(2), P2-P2, 2005.
Gastonguay MR, Venitz J, Steffen R, Hackman J. Population Pharmacokinetic–Pharmacodynamic Modeling of Efaproxiral in Cancer Patients Receiving Radiation Therapy. Clinical Pharmacology and Therapeutics. 77(2), P89-P89, 2005.
Gastonguay MR and Hane JT. The Importance of the Simulation Expectation as a Goodness of Fit Diagnostic for Categorical Population Pharmacodynamic Models. The AAPS Journal; 6(S1), Abstract W4355, 2004.
Gastonguay MR. A Full Model Estimation Approach for Covariate Effects: Inference Based on Clinical Importance and Estimation Precision. The AAPS Journal; 6(S1), Abstract W4354, 2004.
Gastonguay MR and Bies R. Estimation and Prediction of Chaotic Pharmacodynamic Systems Using Nonlinear Mixed-Effects Models: The Butterfly Effect. The AAPS Journal; 6(S1), Abstract W4353, 2004.